Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Ovarian Neoplasms

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 49 articles:
HTML format



Single Articles


    September 2022
  1. TEW WP, Lacchetti C, Kohn EC
    Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Sep 23:JCO2201934. doi: 10.1200/JCO.22.01934.
    PubMed     Abstract available


  2. DISILVESTRO P, Banerjee S, Colombo N, Scambia G, et al
    Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
    J Clin Oncol. 2022 Sep 9:JCO2201549. doi: 10.1200/JCO.22.01549.
    PubMed     Abstract available


  3. TANYI JL, Randall LM, Chambers SK, Butler KA, et al
    A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
    J Clin Oncol. 2022 Sep 7:JCO2200291. doi: 10.1200/JCO.22.00291.
    PubMed     Abstract available


    August 2022
  4. SPILSBURY K, Tuesley KM, Pearson SA, Coory MD, et al
    Perioperative Beta-Blocker Supply and Survival in Women With Epithelial Ovarian Cancer and a History of Cardiovascular Conditions.
    J Clin Oncol. 2022 Aug 24:JCO2200097. doi: 10.1200/JCO.22.00097.
    PubMed     Abstract available


  5. HAMPEL H, Yurgelun MB
    Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?
    J Clin Oncol. 2022;40:2681-2692.
    PubMed     Abstract available


  6. FU S, Corr BR, Culm-Merdek K, Mockbee C, et al
    Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
    J Clin Oncol. 2022;40:2568-2577.
    PubMed     Abstract available


  7. LI N, Zhang Y, Wang J, Zhu J, et al
    Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
    J Clin Oncol. 2022;40:2436-2446.
    PubMed     Abstract available


    July 2022
  8. HURWITZ LM, Townsend MK, Jordan SJ, Patel AV, et al
    Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.
    J Clin Oncol. 2022 Jul 22:JCO2101900. doi: 10.1200/JCO.21.01900.
    PubMed     Abstract available


  9. BETANCOURT NJ, Qian MF, Pickford JR, Bailey-Healy I, et al
    Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease Severity.
    J Clin Oncol. 2022;40:2119-2127.
    PubMed     Abstract available


    June 2022
  10. PHILLIPS KA, Friedlander ML
    Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?
    J Clin Oncol. 2022;40:1850-1852.
    PubMed    


  11. STEENBEEK MP, van Bommel MHD, Bulten J, Hulsmann JA, et al
    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Clin Oncol. 2022;40:1879-1891.
    PubMed     Abstract available


  12. MONK BJ, Parkinson C, Lim MC, O'Malley DM, et al
    A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
    J Clin Oncol. 2022 Jun 6:JCO2201003. doi: 10.1200/JCO.22.01003.
    PubMed     Abstract available


    May 2022
  13. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
    Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
    J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.
    PubMed    


  14. LIEBERMAN S, Goldvaser H, Levy-Lahad E
    Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers.
    J Clin Oncol. 2022;40:1590-1594.
    PubMed    


  15. LI S, Silvestri V, Leslie G, Rebbeck TR, et al
    Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.
    J Clin Oncol. 2022;40:1529-1541.
    PubMed     Abstract available


  16. DONOVAN HS, Sereika SM, Wenzel LB, Edwards RP, et al
    Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259).
    J Clin Oncol. 2022;40:1464-1473.
    PubMed     Abstract available


    March 2022
  17. POWELL MA, Filiaci VL, Hensley ML, Huang HQ, et al
    Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
    J Clin Oncol. 2022;40:968-977.
    PubMed     Abstract available


  18. LIU JF, Brady MF, Matulonis UA, Miller A, et al
    Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
    J Clin Oncol. 2022 Mar 15:JCO2102011. doi: 10.1200/JCO.21.02011.
    PubMed     Abstract available


  19. DELAHUNTY R, Nguyen L, Craig S, Creighton B, et al
    TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    J Clin Oncol. 2022 Mar 9:JCO2102108. doi: 10.1200/JCO.21.02108.
    PubMed     Abstract available


    February 2022
  20. BAEK MH, Park EY, Ha HI, Park SY, et al
    Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis.
    J Clin Oncol. 2022 Feb 21:JCO2102085. doi: 10.1200/JCO.21.02085.
    PubMed     Abstract available


  21. ANG BH, Ho WK, Wijaya E, Kwan PY, et al
    Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer.
    J Clin Oncol. 2022 Feb 10:JCO2101647. doi: 10.1200/JCO.21.01647.
    PubMed     Abstract available


    January 2022
  22. BILASH T, Walker LM
    Spare Parts: Navigating Ovarian Cancer as a Transgender Man.
    J Clin Oncol. 2022 Jan 12:JCO2101249. doi: 10.1200/JCO.21.01249.
    PubMed    


    December 2021
  23. MO DC, Ren T
    Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2021 Dec 10:JCO2102208. doi: 10.1200/JCO.21.02208.
    PubMed    


    September 2021
  24. PORTER RL, Matulonis UA
    Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer.
    J Clin Oncol. 2021 Sep 16:JCO2101886. doi: 10.1200/JCO.21.01886.
    PubMed    


  25. HAMANISHI J, Takeshima N, Katsumata N, Ushijima K, et al
    Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
    J Clin Oncol. 2021 Sep 2:JCO2100334. doi: 10.1200/JCO.21.00334.
    PubMed     Abstract available


    May 2021
  26. ZIVANOVIC O, Chi DS, Zhou Q, Iasonos A, et al
    Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
    J Clin Oncol. 2021 May 21:JCO2100605. doi: 10.1200/JCO.21.00605.
    PubMed     Abstract available


    April 2021
  27. MOORE KN, Bookman M, Sehouli J, Miller A, et al
    Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
    J Clin Oncol. 2021 Apr 23:JCO2100306. doi: 10.1200/JCO.21.00306.
    PubMed     Abstract available


  28. KONSTANTINOPOULOS PA, Cannistra SA
    Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?
    J Clin Oncol. 2021 Apr 23:JCO2100571. doi: 10.1200/JCO.21.00571.
    PubMed    


    February 2021
  29. KURIAN AW, Ward KC, Abrahamse P, Bondarenko I, et al
    Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785.
    PubMed     Abstract available


    November 2020
  30. MONK BJ, Grisham RN, Banerjee S, Kalbacher E, et al
    MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
    J Clin Oncol. 2020;38:3753-3762.
    PubMed     Abstract available


    October 2020
  31. OZA AM, Lorusso D, Aghajanian C, Oaknin A, et al
    Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
    J Clin Oncol. 2020;38:3494-3505.
    PubMed     Abstract available


    September 2020
  32. GERSHENSON DM, Gourley C, Paul J
    MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.
    J Clin Oncol. 2020 Sep 8:JCO2002190. doi: 10.1200/JCO.20.02190.
    PubMed    


    August 2020
  33. TEW WP, Lacchetti C, Ellis A, Maxian K, et al
    PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Aug 13:JCO2001924. doi: 10.1200/JCO.20.01924.
    PubMed     Abstract available


  34. PAULINO E, Melo AC
    SOLO 3 Trial: How Do the Results Fit in With Current Evidence?
    J Clin Oncol. 2020;38:2697-2698.
    PubMed    


  35. PENSON RT, Lowe ES
    Reply to E. Paulino et al.
    J Clin Oncol. 2020;38:2698.
    PubMed    


  36. DISILVESTRO P, Colombo N, Scambia G, Kim BG, et al
    Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
    J Clin Oncol. 2020 Aug 4:JCO2000799. doi: 10.1200/JCO.20.00799.
    PubMed     Abstract available


    April 2020
  37. ZAMARIN D, Burger RA, Sill MW, Powell DJ Jr, et al
    Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
    J Clin Oncol. 2020 Apr 10:JCO1902059. doi: 10.1200/JCO.19.02059.
    PubMed     Abstract available


    March 2020
  38. BEEBE-DIMMER JL, Kapron AL, Fraser AM, Smith KR, et al
    Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
    J Clin Oncol. 2020 Mar 24:JCO1902808. doi: 10.1200/JCO.19.02808.
    PubMed     Abstract available


  39. YANG X, Leslie G, Doroszuk A, Schneider S, et al
    Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
    J Clin Oncol. 2020;38:674-685.
    PubMed     Abstract available


    February 2020
  40. PENSON RT, Valencia RV, Cibula D, Colombo N, et al
    Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
    J Clin Oncol. 2020 Feb 19:JCO1902745. doi: 10.1200/JCO.19.02745.
    PubMed     Abstract available


    January 2020
  41. KONSTANTINOPOULOS PA, Norquist B, Lacchetti C, Armstrong D, et al
    Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Jan 27:JCO1902960. doi: 10.1200/JCO.19.02960.
    PubMed     Abstract available


  42. TEWARI KS, Monk BJ, Burger RA
    Reply to Farolfi et al and Haines et al.
    J Clin Oncol. 2020;38:173-174.
    PubMed    


    November 2019
  43. HAINES IE, Gabor Miklos GL
    Bevacizumab Moonshots: An Important Outcome From the Latest Ovarian Cancer Mission.
    J Clin Oncol. 2019 Nov 7:JCO1901912. doi: 10.1200/JCO.19.01912.
    PubMed    


  44. FAROLFI A, Lorusso D, Pignata S, De Giorgi U, et al
    Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.
    J Clin Oncol. 2019 Nov 7:JCO1902055. doi: 10.1200/JCO.19.02055.
    PubMed    


    September 2019
  45. DE JAEGHERE EA, Gremonprez FB, Tummers PG, Willaert WC, et al
    Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate.
    J Clin Oncol. 2019 Sep 25:JCO1901179. doi: 10.1200/JCO.19.01179.
    PubMed    


  46. TOMAO F, Benedetti Panici P, Tomao S
    Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Old and Novel Questions.
    J Clin Oncol. 2019 Sep 25:JCO1901163. doi: 10.1200/JCO.19.01163.
    PubMed    


    April 2019
  47. BAE JM, Chung KY, Yun SJ, Kim H, et al
    Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study.
    J Clin Oncol. 2019;37:903-911.
    PubMed     Abstract available


    February 2019
  48. FONSECA A, Xia C, Lorenzo AJ, Krailo M, et al
    Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.
    J Clin Oncol. 2019;37:396-402.
    PubMed     Abstract available


    January 2019
  49. BOULAY RM
    The Boy I Never Knew.
    J Clin Oncol. 2019;37:254-255.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: